The productivity crisis in drug development: why greater investment does not automatically lead to more innovation

Over recent decades, the pharmaceutical industry has achieved unprecedented progress. Breakthroughs in genomics, artificial intelligence, high-throughput screening, single-cell sequencing and advanced analytical technologies have fundamentally transformed the possibilities within research and discovery. At the same time, global investment in research and development has increased exponentially.

Yet the sector faces a striking paradox. Despite larger budgets, greater scientific knowledge and more powerful technologies, drug development productivity is not increasing at the same rate. Developing new therapies remains costly, high-risk and time-consuming.

This development, often described as Eroom’s Law, the inverse of Moore’s Law, demonstrates that the cost of each successfully approved medicine has risen consistently over recent decades. The central question is therefore no longer how much organisations invest in R&D, but how effectively those investments are converted into clinically and commercially successful innovations.

The complexity of human biology

One important explanation lies in the increasing complexity of the diseases the sector is seeking to address. While many established medicines were developed for relatively well-understood conditions, attention is now shifting towards oncology, neurodegenerative disorders, autoimmune diseases and rare genetic conditions.

These indications are characterised by complex biological networks, considerable variation between patients and disease processes that are often not yet fully understood. In this context, more data do not automatically generate more knowledge. On the contrary, organisations have access to vast quantities of genetic, molecular and clinical data, but the ability to draw the right scientific conclusions from them is increasingly becoming a differentiating factor.

The challenge is therefore shifting from data collection to data interpretation, and from technological capacity to scientific decision-making.

Why technology alone is insufficient

Innovations such as artificial intelligence, machine learning and automation have undoubtedly secured an important role in modern research and discovery. They accelerate analyses, identify new relationships and help researchers process vast datasets.

Technology, however, does not guarantee successful drug development.

Many programmes fail not because of insufficient data or computing power, but because fundamental biological assumptions prove incorrect. If a therapeutic target has not been adequately validated or the underlying disease biology is not fully understood, even the most advanced algorithms cannot compensate for that uncertainty.

Technology increases the speed at which organisations can make decisions. Whether those decisions are better still depends on scientific expertise, critical evaluation and multidisciplinary collaboration.

The high cost of early strategic decisions

The most important determinants of success in drug development are often established during the earliest stages of research.

Decisions concerning target selection, biomarker strategy, translational research and experimental design influence the entire subsequent development pathway. When incorrect assumptions are made at this stage, the consequences often become apparent only during preclinical or clinical development, when the financial impact is many times greater.

Leading organisations are therefore investing increasingly in robust target validation, integrated data analytics and early decision-making based on multiple independent sources of evidence.

Reducing scientific uncertainty at the beginning of the development process is considerably more effective than correcting mistakes at a later stage.

Productivity requires better decision-making

The most successful R&D organisations are increasingly distinguished not by the size of their budgets, but by the quality of their decision-making processes.

This includes:

Combining genetic, molecular and clinical insights;
Enabling multidisciplinary collaboration across biology, chemistry, bioinformatics and translational science;
Establishing clear portfolio governance with objective decision points;
Discontinuing programmes with insufficient prospects of success at the appropriate time;
Creating a culture in which scientific assumptions are continuously challenged.

These organisations accept that not every research programme will succeed. Their strength lies in identifying risks early, enabling resources to be directed towards projects with the greatest scientific and societal potential.

From more research to smarter research

The future of drug development will not be determined solely by greater investment or new technologies. Competitive advantage is shifting towards organisations capable of combining scientific knowledge, data, technology and experienced decision-making effectively.

This requires researchers who look beyond their own areas of specialisation, leaders capable of navigating complex scientific trade-offs and organisations that promote collaboration between disciplines that have traditionally operated separately.

At a time when drug development continues to become more complex, success will not belong to the organisation with the most data or the largest budget, but to the organisation that makes the best decisions based on the available evidence.

Conclusion

The productivity challenge in research and discovery is not a temporary phenomenon, but a structural reality facing the entire life sciences sector. Although technological innovation is creating unprecedented possibilities, the key to sustainable progress lies not solely in investing more, but in organising more intelligently.

Organisations that excel in scientific decision-making, robust target validation and multidisciplinary collaboration significantly increase their likelihood of successful innovation. This is where the distinction emerges between research that appears promising and research that ultimately delivers new therapies that meaningfully improve patients’ lives.

Working with Maxwell Benson? Discover the possibilities

Werken met Oliver Benson?